DALLAS, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Triumph Financial, Inc. (Nasdaq: TFIN) has released its third quarter 2024 financial results. The 3Q 2024 financial results and shareholder letter are ...
New Fall Brews and Spirits from Tilray Beverages: Shock Top: Twisted Pretzel (ABV: 5%): Shock Top has united the classic ...
Creator and marketing company Triller went public on the Nasdaq via a reverse merger with a Hong Kong-based company called ...
Piper Sandler and Oppenheimer & Co. are acting as the joint book-running managers for the public offering. The Company intends to use the net proceeds from this offering on the continued development ...
In connection with the Merger, AGBA has changed its name to Triller Group Inc. (the “Company”). The combined company’s common stock and warrants are expected to begin trading under the tickers “ILLR” ...
SUNNYVALE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (the “Company” or “23andMe”), announced today the ...
The previously announced reverse stock split to comply with Nasdaq’s rules in connection with the merger will take effect on October 15, 2024.NEW ...
On October 9, 2024, Sky Quarry announced it closed a Public Offering of $6,708,030 through the sale of 1,118,005 shares of its Common Stock priced at $6.00 per share.
John’s extensive experience in financial strategy and investor engagement will be critical as TeraWulf continues to scale and execute our growth plans,” said Paul Prager. “His deep expertise in ...
Meanwhile, a report that the US is considering export caps on specific chip sales only added to investor concern, pulling the broader chip sector lower. Nvidia shed over 5%, while Broadcom dropped ...
NEW YORK, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today reported monthly volumes for September 2024, as well as quarterly volumes, estimated revenue capture, number of listings, and ...
INVO Bioscience (“INVO”) (NASDAQ: INVO) today announced it has closed its merger with NAYA Biosciences, a company dedicated to increasing patient access to breakthrough treatments in oncology and ...